IL271100A - A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus - Google Patents

A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Info

Publication number
IL271100A
IL271100A IL271100A IL27110019A IL271100A IL 271100 A IL271100 A IL 271100A IL 271100 A IL271100 A IL 271100A IL 27110019 A IL27110019 A IL 27110019A IL 271100 A IL271100 A IL 271100A
Authority
IL
Israel
Prior art keywords
patients
reducing
type
diabetes mellitus
cardiovascular events
Prior art date
Application number
IL271100A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL271100A publication Critical patent/IL271100A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IL271100A 2017-06-12 2019-12-02 A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus IL271100A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518547P 2017-06-12 2017-06-12
PCT/IB2018/054208 WO2018229630A1 (en) 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Publications (1)

Publication Number Publication Date
IL271100A true IL271100A (en) 2020-01-30

Family

ID=62916717

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271100A IL271100A (en) 2017-06-12 2019-12-02 A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Country Status (15)

Country Link
US (2) US20180353470A1 (https=)
EP (1) EP3638250A1 (https=)
JP (2) JP2020523408A (https=)
KR (1) KR20200014406A (https=)
CN (1) CN110740735A (https=)
AU (1) AU2018283781B2 (https=)
BR (1) BR112019026120A2 (https=)
CA (1) CA3066874A1 (https=)
CO (1) CO2019013940A2 (https=)
EA (1) EA202090028A1 (https=)
IL (1) IL271100A (https=)
MX (1) MX2019014988A (https=)
TW (1) TWI835735B (https=)
UA (1) UA127987C2 (https=)
WO (1) WO2018229630A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230046951A1 (en) * 2021-08-03 2023-02-16 National Chengchi University System and method for assessing risk of type 2 mellitus diabetes complications
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
NO2385374T3 (https=) * 2010-05-05 2014-06-07
US20130052266A1 (en) * 2010-05-11 2013-02-28 Mitsubishi Tanabe Pharma Corporation TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2015210898A1 (en) * 2014-01-31 2016-07-28 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Also Published As

Publication number Publication date
TWI835735B (zh) 2024-03-21
JP2023113644A (ja) 2023-08-16
EA202090028A1 (ru) 2020-04-03
CO2019013940A2 (es) 2020-01-17
EP3638250A1 (en) 2020-04-22
CA3066874A1 (en) 2018-12-20
MX2019014988A (es) 2020-08-06
JP2020523408A (ja) 2020-08-06
BR112019026120A2 (pt) 2020-07-07
US20210000792A1 (en) 2021-01-07
US20180353470A1 (en) 2018-12-13
AU2018283781A1 (en) 2019-12-19
CN110740735A (zh) 2020-01-31
AU2018283781B2 (en) 2023-09-28
KR20200014406A (ko) 2020-02-10
UA127987C2 (uk) 2024-03-06
WO2018229630A1 (en) 2018-12-20
TW201904584A (zh) 2019-02-01

Similar Documents

Publication Publication Date Title
ZA202007993B (en) Methods of reducing the risk of cardiovascular events in a subject
TWI563057B (en) Adhesive film, adhesive composition, and display apparatus including the same
PL2948102T3 (pl) Zastawka do krótkoterminowej wymiany w celu przejęcia działania i/lub czasowego albo częściowego wspomagania naturalnej zastawki serca
PL3283551T3 (pl) Kompozycja aktywowanej ligniny, sposób jej wytwarzania oraz jej zastosowanie
EP3085632A4 (en) Printed film for vessel, and method for manufacturing same
EP3113627A4 (en) Low calorie sugar substitute composition and methods for making the same
EP3175619A4 (en) Golden frame selection in video coding
IL254496A0 (en) Treatment of type 2 diabetes patients
EP3094968A4 (en) Metabolic screening for gestational diabetes
IL273016A (en) Genotype stratification in the treatment and prevention of diabetes
PL3365507T3 (pl) Struktura wielowarstwowa zawierająca vip i sposób jej wytwarzania
SG11201803938RA (en) Polymetalloxane, method for producing same, composition thereof, cured film and method for producing same, and members and electronic components provided with same
PL3027055T3 (pl) Pochodząca z ziemniaków kompozycja wzmacniacza smaku i sposób jej wytwarzania
IL271100A (en) A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
EP3053449A4 (en) Fat composition for non-tempered chocolate and fat composition for tempered chocolate
ZA201509103B (en) A composition, process and a kit for sugar processing
GB201807648D0 (en) A frame for use in connection with a structure
EP2964236A4 (en) CAMELID COMPOUND (EN), COMPOSITION (S) AND METHOD
EP3013958A4 (en) Glucan-encapsulated sirna for treating type 2 diabetes mellitus
SG10201801518YA (en) Composition for improving blood sugar metabolism
GB201507914D0 (en) A picture frame, a picture frame kit and a method for making a picture frame
GB201519697D0 (en) Screen having frame members with angled surface(s)
GB201803519D0 (en) Improvements in frying technology
PT3007683T (pt) Composição para administração oral de magnésio, em associação com uma composição para o tratamento de diabetes tipo 2 e suas complicações
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes